Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KX1-004 是非 ATP 竞争性 Src-PTK 抑制剂,IC50=40 μM。它能够保护耳蜗,使其免受有害噪音的影响,并防止噪音引起的听力损失 (NIHL)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 378 | 现货 | ||
2 mg | ¥ 546 | 现货 | ||
5 mg | ¥ 913 | 现货 | ||
10 mg | ¥ 1,630 | 现货 | ||
25 mg | ¥ 2,750 | 现货 | ||
50 mg | ¥ 3,930 | 现货 | ||
100 mg | ¥ 5,730 | 现货 | ||
500 mg | ¥ 11,500 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 983 | 现货 |
产品描述 | KX1-004, a potential protective drug for NIHL, is an effective small molecule inhibitor of Src-PTK. |
靶点活性 | Src PTK:40 μM |
激酶实验 | The Lck HTRF kinase assay involves ATP-dependent phosphorylation of a biotinylated substrate peptide of gastrin in the presence or absence of inhibitor compound. The final concentration of gastrin is 1.2 μM. The final concentration of ATP is 0.5 μM (Km app =0.6±0.1 μM), and the final concentration of Lck (a GST-kinase domain fusion (AA 225?509)) is 250 pM. Buffer conditions are as follows: 50 mM HEPES pH=7.5, 50 mM NaCl, 20 mM MgCl2, 5 mM MnCl2, 2 mM DTT, 0.05% BSA. The assay is quenched and stopped with 160 μL of detection reagent. Detection reagents are as follows: Buffer made of 50 mM Tris, pH=7.5, 100 mM NaCl, 3 mM EDTA, 0.05% BSA, 0.1% Tween20. Prior to reading, Streptavidin allophycocyanin (SA-APC) is added at a final concentration in the assay of 0.0004 mg/mL, along with europilated anti-phosphotyrosine Ab (Eu-anti-PY) at a final conc of 0.025 nM. The assay plate is read in a Discovery fluorescence plate reader with excitation at 320 nm and emission at 615 and 655 nm[1]. |
别名 | KX1 004, KX1004 |
分子量 | 284.29 |
分子式 | C16H13FN2O2 |
CAS No. | 518058-84-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (211.05 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.5175 mL | 17.5877 mL | 35.1753 mL | 87.9384 mL |
5 mM | 0.7035 mL | 3.5175 mL | 7.0351 mL | 17.5877 mL | |
10 mM | 0.3518 mL | 1.7588 mL | 3.5175 mL | 8.7938 mL | |
20 mM | 0.1759 mL | 0.8794 mL | 1.7588 mL | 4.3969 mL | |
50 mM | 0.0704 mL | 0.3518 mL | 0.7035 mL | 1.7588 mL | |
100 mM | 0.0352 mL | 0.1759 mL | 0.3518 mL | 0.8794 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
KX1-004 518058-84-9 Angiogenesis Tyrosine Kinase/Adaptors Src noise cells inhibit hearing KX1 004 exposure KX1004 Inhibitor KX 1004 KX-1004 loss KX-1-004 hair inhibitor